{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T08:12:23Z","timestamp":1788595943787,"version":"build-2803163510"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,5]]},"DOI":"10.7759\/cureus.115808","type":"journal-article","created":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T07:55:06Z","timestamp":1788594906000},"source":"Crossref","is-referenced-by-count":0,"title":["Etomidate Monotherapy for Perioperative Control of Hypercortisolism in a Mitotane-Intolerant Patient With Adrenocortical Carcinoma: A Case Report"],"prefix":"10.7759","author":[{"given":"Naeem","family":"Alkheamy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jalal","family":"Jbara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nissar","family":"Shaikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umm E","family":"Amara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umme","family":"Nashrah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahzad","family":"Anjum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gamal","family":"Al-Ameri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1159\/000314297","article-title":"Epidemiology of Cushing's syndrome","volume":"92","author":"Steffensen C","year":"2010","unstructured":"Steffensen C, Bak AM, Rubeck KZ, J\u00f8rgensen JO. Epidemiology of Cushing's syndrome. Neuroendocrinology. 2010, 92:1-5. 10.1159\/000314297","journal-title":"Neuroendocrinology"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2013.07.003","article-title":"Glucocorticoid receptor signaling in health and disease","volume":"34","author":"Kadmiel M","year":"2013","unstructured":"Kadmiel M, Cidlowski JA. Glucocorticoid receptor signaling in health and disease. Trends Pharmacol Sci. 2013, 34:518-30. 10.1016\/j.tips.2013.07.003","journal-title":"Trends Pharmacol Sci"},{"key":"ref3","article-title":"Physiology, cortisol","author":"Thau L","year":"2023","unstructured":"Thau L, Gandhi J, Sharma S. Physiology, cortisol. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2023."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1097\/ALN.0b013e3181ff72b5","article-title":"Clinical and molecular pharmacology of etomidate","volume":"114","author":"Forman SA","year":"2011","unstructured":"Forman SA, Warner DS. Clinical and molecular pharmacology of etomidate. Anesthesiology. 2011, 114:695-707. 10.1097\/ALN.0b013e3181ff72b5","journal-title":"Anesthesiology"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-021-01038-6","article-title":"Etomidate and its analogs: a review of pharmacokinetics and pharmacodynamics","volume":"60","author":"Valk BI","year":"2021","unstructured":"Valk BI, Struys MM. Etomidate and its analogs: a review of pharmacokinetics and pharmacodynamics. Clin Pharmacokinet. 2021, 60:1253-69. 10.1007\/s40262-021-01038-6","journal-title":"Clin Pharmacokinet"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1994.tb02486.x","article-title":"Morbidity and mortality in Cushing's disease: an epidemiological approach","volume":"40","author":"Etxabe J","year":"1994","unstructured":"Etxabe J, Vazquez JA. Morbidity and mortality in Cushing's disease: an epidemiological approach. Clin Endocrinol (Oxf). 1994, 40:479-84. 10.1111\/j.1365-2265.1994.tb02486.x","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61375-1","article-title":"Cushing's syndrome","volume":"386","author":"Lacroix A","year":"2015","unstructured":"Lacroix A, Feelders RA, Stratakis CA, Nieman LK. Cushing's syndrome. Lancet. 2015, 386:913-27. 10.1016\/S0140-6736(14)61375-1","journal-title":"Lancet"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab058","article-title":"Acute and life-threatening complications in Cushing syndrome: prevalence, predictors, and mortality","volume":"106","author":"Schernthaner-Reiter MH","year":"2021","unstructured":"Schernthaner-Reiter MH, Siess C, Micko A, et al.. Acute and life-threatening complications in Cushing syndrome: prevalence, predictors, and mortality. J Clin Endocrinol Metab. 2021, 106:e2035-46. 10.1210\/clinem\/dgab058","journal-title":"J Clin Endocrinol Metab"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecl.2019.08.005","article-title":"Hypertension and cardiovascular mortality in patients with Cushing syndrome","volume":"48","author":"Nieman LK","year":"2019","unstructured":"Nieman LK. Hypertension and cardiovascular mortality in patients with Cushing syndrome. Endocrinol Metab Clin North Am. 2019, 48:717-25. 10.1016\/j.ecl.2019.08.005","journal-title":"Endocrinol Metab Clin North Am"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2011.04253.x","article-title":"Subclinical Cushing's syndrome: definition and management","volume":"76","author":"Terzolo M","year":"2012","unstructured":"Terzolo M, Pia A, Reimondo G. Subclinical Cushing's syndrome: definition and management. Clin Endocrinol (Oxf). 2012, 76:12-8. 10.1111\/j.1365-2265.2011.04253.x","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-1818","article-title":"Treatment of Cushing's syndrome: an Endocrine Society clinical practice guideline","volume":"100","author":"Nieman LK","year":"2015","unstructured":"Nieman LK, Biller BM, Findling JW, Murad MH, Newell-Price J, Savage MO, Tabarin A. Treatment of Cushing's syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2015, 100:2807-31. 10.1210\/jc.2015-1818","journal-title":"J Clin Endocrinol Metab"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa778","article-title":"Adrenally directed medical therapies for Cushing syndrome","volume":"106","author":"Tritos NA","year":"2021","unstructured":"Tritos NA. Adrenally directed medical therapies for Cushing syndrome. J Clin Endocrinol Metab. 2021, 106:16-25. 10.1210\/clinem\/dgaa778","journal-title":"J Clin Endocrinol Metab"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-0536","article-title":"Mitotane, metyrapone, and ketoconazole combination therapy as an alternative to rescue adrenalectomy for severe ACTH-dependent Cushing's syndrome","volume":"96","author":"Kamenick\u00fd P","year":"2011","unstructured":"Kamenick\u00fd P, Droumaguet C, Salenave S, et al.. Mitotane, metyrapone, and ketoconazole combination therapy as an alternative to rescue adrenalectomy for severe ACTH-dependent Cushing's syndrome. J Clin Endocrinol Metab. 2011, 96:2796-804. 10.1210\/jc.2011-0536","journal-title":"J Clin Endocrinol Metab"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-14-0913","article-title":"Rapid control of severe neoplastic hypercortisolism with metyrapone and ketoconazole","volume":"172","author":"Corcuff JB","year":"2015","unstructured":"Corcuff JB, Young J, Masquefa-Giraud P, Chanson P, Baudin E, Tabarin A. Rapid control of severe neoplastic hypercortisolism with metyrapone and ketoconazole. Eur J Endocrinol. 2015, 172:473-81. 10.1530\/EJE-14-0913","journal-title":"Eur J Endocrinol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1177\/2042018819825541","article-title":"Low-dose etomidate for the management of severe hypercortisolaemia in different clinical scenarios: a case series and review of the literature","volume":"10","author":"\u0141ebek-Szata\u0144ska A","year":"2019","unstructured":"\u0141ebek-Szata\u0144ska A, Nowak KM, Zgliczy\u0144ski W, Baum E, \u017by\u0142ka A, Papierska L. Low-dose etomidate for the management of severe hypercortisolaemia in different clinical scenarios: a case series and review of the literature. Ther Adv Endocrinol Metab. 2019, 10:25541. 10.1177\/2042018819825541","journal-title":"Ther Adv Endocrinol Metab"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1210\/js.2018-00269","article-title":"Continuous etomidate infusion for the management of severe Cushing syndrome: validation of a standard protocol","volume":"3","author":"Carroll TB","year":"2019","unstructured":"Carroll TB, Peppard WJ, Herrmann DJ, et al.. Continuous etomidate infusion for the management of severe Cushing syndrome: validation of a standard protocol. J Endocr Soc. 2019, 3:1-12. 10.1210\/js.2018-00269","journal-title":"J Endocr Soc"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/522557-etomidate-monotherapy-for-perioperative-control-of-hypercortisolism-in-a-mitotane-intolerant-patient-with-adrenocortical-carcinoma-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T07:55:06Z","timestamp":1788594906000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/522557-etomidate-monotherapy-for-perioperative-control-of-hypercortisolism-in-a-mitotane-intolerant-patient-with-adrenocortical-carcinoma-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,5]]},"references-count":16,"URL":"https:\/\/doi.org\/10.7759\/cureus.115808","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9,5]]}}}